Patients with metastatic melanoma taking the recently approved drug vemurafenib (marketed as Zelboraf) responded well to the twice-daily pill, but some of them developed a different, secondary skin cancer.
Now, researchers at UCLA’s Jonsson Comprehensive Cancer Center, working with investigators from the Institute of Cancer Research in London, Roche and Plexxikon, have elucidated the mechanism by which the drug excels at fighting melanoma but also allows for the development of skin squamous-cell carcinomas.(more…)
*University of Missouri investigators’ discovery sheds light on how plants fight off bacterial infections*
Columbia, MO — Like us, plants rely on an immune system to fight off disease. Proteins that scout out malicious bacterial invaders in the cell and communicate their presence to the nucleus are important weapons in the plant’s disease resistance strategy. Researchers at the University of Missouri recently “tapped” into two proteins’ communications with the nucleus and discovered a previously unknown level of cross talk. The discovery adds important new information about how plant proteins mediate resistance to bacteria that cause disease and may ultimately lead to novel strategies for boosting a plant’s immune system.
Special proteins in the plant, called resistance proteins, can recognize highly specific features of proteins from pathogen, called effector proteins. When a pathogen is detected, a resistance protein triggers an “alarm” that communicates the danger to the cell’s nucleus. The communication between the resistance protein and nucleus occurs through a mechanism called a signaling pathway. (more…)
